Forty two patients (22 adults and 20 children or adolescents) with cerebral dysrithmia were included in a therapeutic trial using barbexaclone: 28 patients suffered from grand mal crises, 2 had associated GM and petit mal and 12 showed disturbances of behaviour without clinical crises. The patients were observed from 6 to 13 months. Four patients failed to complete the trial due to various side effects; 25 patients with GM and 11 with behaviour disturbances showed a very good response; two patients with associated petit mal failed to show any improvement. Side effects such as insomnia and irritability were seen in 8 patients. The authors concluded that barbexaclone is an excellent therapeutic agent in the treatment of grand mal and in patients with behaviour disturbances without convulsive crises.